<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848182</url>
  </required_header>
  <id_info>
    <org_study_id>2016-7197</org_study_id>
    <secondary_id>422247</secondary_id>
    <nct_id>NCT03848182</nct_id>
  </id_info>
  <brief_title>Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer</brief_title>
  <official_title>Analysis of T Cells to Tetanus Toxoid Antigens in Patients With Pancreatic Cancer Treated With Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pancreatic Cancer Action Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator is developing an immune therapy against pancreatic cancer. Immune cells,
      known as &quot;T cells with tumor killing capacity&quot;, are involved in this immune therapy. In mice
      with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that
      patients receive from childhood) combined with Gemcitabine activates these killer T cells.
      (Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells
      uploaded with TT protein (such studies are planned in future clinical trials). The goal of
      this study is to test whether one TT vaccination combined with Gemcitabine treatment
      activates the same T cells in pancreatic cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Actual">November 11, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD4 T cell responses before TT booster vaccine</measure>
    <time_frame>Day 8</time_frame>
    <description>Blood will be drawn</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CD4 T cell responses after TT booster vaccine</measure>
    <time_frame>Day 8</time_frame>
    <description>Blood will be drawn</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CD8 T cell responses before TT booster vaccine</measure>
    <time_frame>Day 8</time_frame>
    <description>Blood will be drawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD8 T cell responses after TT booster vaccine</measure>
    <time_frame>Day 8</time_frame>
    <description>Blood will be drawn</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in myeloid-derived suppressor cells</measure>
    <time_frame>Day 8</time_frame>
    <description>Blood will be drawn</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine with TT vaccine booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered on days 1, 8, 15 every 28 days</description>
    <arm_group_label>Gemcitabine with TT vaccine booster</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TT vaccine booster</intervention_name>
    <description>One human TT childhood vaccine booster will be administered on day 8</description>
    <arm_group_label>Gemcitabine with TT vaccine booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally
             advanced, borderline resectable settings all permitted)

          3. Patients at least 18 years of age

          4. ECOG performance status 0-2

          5. Consent to donate 12 tubes of peripheral blood of 10 mL each

          6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000
             -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30

          7. Ability to understand and willingness to sign a written informed consent document

          8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior
             radiation therapy permitted, as long as 28 days lapsed since last treatment.

          9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy

        Exclusion Criteria:

          1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of
             adverse reaction to tetanus vaccine (with the exception of self-limited fever or local
             tissue reaction

          2. Patients may not be receiving any investigational agents

          3. Pregnant women

          4. Patients with HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gravekamp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Claudia Gravekamp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>T-cell responses</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Perforin</keyword>
  <keyword>Granzyme-B</keyword>
  <keyword>Myeloid-derived suppressor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

